Look up one drug

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Quetiapine · DIN 02317907 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2010-06-14 Health Canada: Marketed since 2016-08-12 · brand QUETIAPINE · ATC N05AH04 QUETIAPINE · form Tablet · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 100 MG · company Sivem pharmaceuticals ulc · schedule Prescription

DIN 02317907: Quetiapine Raw flags: sec3=Y Item: 281608192; group id 506; item number 1322; lccId None; manufacturer id SIV Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.1318; ministry $0.1318 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02317907 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80342

Interchangeable products

Act Quetiapine · DIN 02316099 · $0.1318 Apo-Quetiapine · DIN 02313928 · $0.1318 Apo-Quetiapine Fumarate · DIN 02501643 · $0.1318 Auro-Quetiapine · DIN 02390213 · $0.1318 Bio-Quetiapine · DIN 02447207 · $0.1318 Jamp Quetiapine Fumarate · DIN 02390159 · $0.1318 Jamp-Quetiapine · DIN 02330423 · $0.1318 Mar-Quetiapine · DIN 02399830 · $0.1318 Mint-Quetiapine · DIN 02438011 · $0.1318 PMS-Quetiapine · DIN 02296578 · $0.1318 Quetiapine · DIN 02353172 · $0.1318 Quetiapine Tablets · DIN 02387808 · $0.1318 Ran-Quetiapine · DIN 02397102 · $0.1318 Sandoz Quetiapine · DIN 02314002 · $0.1318 Seroquel · DIN 02236952 · $0.1318 Teva-Quetiapine · DIN 02284243 · $0.1318

Shortage status: resolved shortage (ended 2023-06-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02317907

Shortage record checked 2026-09-13T08:10:21.292534+00:00